Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned an average rating of “Moderate Buy” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Four ...

DexCom (NASDAQ:DXCM – Get Free Report) had its price objective increased by research analysts at Barclays from $90.00 to $93.00 in a report issued on Monday,Benzinga reports. The brokerage presently ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

Morgan Stanley upgrades shares of the medtech to Overweight from Equal Weight.

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...